| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445785 | European Journal of Cancer | 2012 | 10 Pages |
Abstract
The reduced pharmacokinetic variability and improved control of busulfan AUC observed following IV administration support its utility within the ongoing HR-NBL-1/SIOPEN trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
G.J. Veal, L. Nguyen, A. Paci, M. Riggi, M. Amiel, D. Valteau-Couanet, P. Brock, R. Ladenstein, G. Vassal,